Cohance says CAPA filed for six USFDA observations

Regulatory & Legal View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹909.80

prior close

₹910.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.1%-0.5% vs market

Pharmaceuticals peers, median of 153sector+0.1%-0.5% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Smallcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.5

15m

+0.6

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4+0.1-0.5+0.1-0.5

Next day

-0.6-0.8+0.2-0.8+0.2

-1.1-1.3+0.2-0.9-0.1

-0.4-1.8+1.4-1.2+0.8

-2.0-2.5+0.5-2.3+0.3

-5.1-4.6-0.6-4.1-1.1

-3.6-4.5+0.9-4.2+0.6

15d

-2.6-2.4-0.2-3.5+0.9

-3.5-1.8-1.7-3.5+0.0

-35.9-3.0-32.8-6.3-29.5

-41.0-6.1-34.8-8.6-32.4

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance clarified media reports about six USFDA observations following an inspection of its Nacharam finished dosage facility. The company said it filed a corrective and preventive action plan on time and is working with the USFDA. US revenue from the facility was below 2% of FY2025 consolidated revenue, while related earnings before interest, tax, depreciation and amortization were below 1%.

Likely market impact

The facility contributes little to revenue and profit, limiting financial exposure, but compliance issues could affect future US business.